Creatinolfosfate

DB13071InvestigationalSmall molecule

COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease. COP has been investigated for the treatment of Diabetic Retinopathy.

Formula / weight: C₄H₁₂N₃O₄P · 197.131 g/mol (avg)

Resolves to

Compound

UNII5O564RN1QDCAS6903-79-3ChEMBLCHEMBL2104114ChEBI134856PubChem23342

Clinical / RWD

ATCC01EB05

Structure

InChIKeyFOIPWTMKYXWFGC-UHFFFAOYSA-NSMILESCN(CCOP(O)(O)=O)C(N)=N

What you can answer from here — as of February 21, 2021

1ATC codeIncluding every combination product, plus 1 drug category

Which companies are running trials of Creatinolfosfate, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account